Biotech Analyst Devarakonda discusses cardiovascular disease with CV expert and Tourmaline Bio management (TRML) on an Analyst/Industry conference call to be held on April 8 at 12 pm. Webcast Link
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML:
- Tourmaline Bio’s TOUR006: Potential Best-in-Class IL-6 Treatment with Strategic Market Positioning
- Positive Buy Rating for Tourmaline Bio Driven by Promising Pacibekitug Developments and Strategic Value
- Tourmaline Bio price target raised to $43 from $42 at Wedbush
- Buy Rating for Tourmaline Bio: Potential of Pacibekitug and Upcoming CKD Data Release
- Tourmaline Bio’s Promising Clinical Trials and Financial Outlook Justify Buy Rating